Diabetes type 2. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Vanadium enriched yeast, 150 mg capsule, 2 per day, for 12 weeks. Intervention 2: Control group: yeast, 150 mg capsule, 2 per day, for 12 weeks.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Willing to participate in the study. Patients in the age range of 30-60 years, except for menopause women. Diagnosed with type 2 diabetes. Not having other malignancies. Having BMI in the range of 30-40 kg/m2. Consuming blood glucose lowering drugs.
Exclusion criteria
Exclusion criteria: Unwilling to participate in the study. Diagnosed with renal, hepatic, heart, rheumatic, inflammatory, intestine and other types of diabetes. Consuming insulin. Changing the type or dose of drugs during the trial. Consuming dietary supplements or complementary therapies, one month prior to trial beginning. Diagnosed with COVID-19 during the trial. Being in special physiologic situation such pregnancy, lactation and menopause. Using opiates and alcohol. Using corticosteroids, NSAID and hormone drugs, 6 months prior to trial beginning. Having a special diet, 6 months prior to trial beginning.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: before and 12 weeks after the intervention. Method of measurement: scale.;Height. Timepoint: before and 12 weeks after the intervention. Method of measurement: stadiometer.;Body Mass Index. Timepoint: before and 12 weeks after the intervention. Method of measurement: Estimation.;Fat percentage. Timepoint: before and 12 weeks after the intervention. Method of measurement: Tanita scale.;Waist Circumference. Timepoint: before and 12 weeks after the intervention. Method of measurement: mounted tape.;Quality of life. Timepoint: before and 12 weeks after the intervention. Method of measurement: Diabetes Quality Of Life Questionnaire.;Fasting blood sugar. Timepoint: before and 12 weeks after the intervention. Method of measurement: Enzymatic.;2hours postprandial blood glucose. Timepoint: before and 12 weeks after the intervention. Method of measurement: Enzymatic.;HbA1C. Timepoint: before and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Fasting insulin. Timepoint: before and 12 weeks after the intervention. Method of measurement: enzyme-linked immunosorbent assay.;HOMA1-IR. Timepoint: before and 12 weeks after the intervention. Method of measurement: formula.;HOMA2-IR. Timepoint: before and 12 weeks after the intervention. Method of measurement: Computer software.;Total cholesterol. Timepoint: before and 12 weeks after the intervention. Method of measurement: Enzymatic.;Triglyceride. Timepoint: before and 12 weeks after the intervention. Method of measurement: Enzymatic.;High-density lipoprotein (HDL) cholesterol. Timepoint: before and 12 weeks after the intervention. Method of measurement: Enzymatic.;Low Density Lipoprotein, Cholesterol (LDL-C). Timepoint: before and 12 weeks after the intervention. Method of measurement: formula.;Expression rate of Protein Tyrosine Phosphatase 1B (PTP1B). Timepoint: before and 12 weeks after the intervention. Method of measurement: Real Time-Polymerase chain reaction.;Expression rate of Ph | — |
Secondary
| Measure | Time frame |
|---|---|
| Energy and Macro-nutrient intake. Timepoint: before and 12 weeks after the intervention. Method of measurement: Questionnaire.;Physical activity. Timepoint: before and 12 weeks after the intervention. Method of measurement: short form-IPAQ. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaezeh Ghalichi
Tabriz University of Medical Sciences
Outcome results
None listed